Clinical application of PCI-32765 for the treatment of B cell malignancies
10.3760/cma.j.issn.1673-422X.2013.06.023
- VernacularTitle:PCI-32765在治疗B细胞恶性肿瘤中的应用
- Author:
Fulian QU
;
Bing XIA
;
Yizhuo ZHANG
- Publication Type:Journal Article
- Keywords:
Lymphoma;
Drug therapy;
Signal transducing
- From:
Journal of International Oncology
2013;(6):472-475
- CountryChina
- Language:Chinese
-
Abstract:
PCI-32765,an oral selective and irreversible inhibitor of Bruton tyrosine kinase (BTK),inhibits survival,activation,proliferation and migration of malignant B cells by blocking B cell receptor signaling pathway.PCI-32765 not only acts on malignant B cell,but also prevents resistance to chemical drugs.Therefore,PCI-32765 has broad prospects in the treatment of B cell malignancies.
